On Monday, Shares of Atmel Corporation (NASDAQ:ATML), gained 4.10% to $8.88.
Atmel Corporation, declared the company will meet with investors in one-on-one and group meetings at the following investor conferences:
- On May 27, Senior Director Investor Relations Peter Schuman will meet with investors at the Craig-Hallum Institutional Investor Conference at the Renaissance Minneapolis Depot Hotel.
- On June 2, Senior Vice President and Chief Financial Officer Steve Skaggs will meet with investors at the Bank of America Merrill Lynch 2014 Global Technology Conference at the Ritz-Carlton Hotel in San Francisco.
- On June 3, Schuman will meet with investors at the Stephens Spring Investment Conference at the New York Palace Hotel.
Atmel Corporation designs, develops, manufactures, and sells semiconductor integrated circuit products primarily in the United States, Asia, Europe, South Africa, and Central and South America. It operates in four segments: Microcontroller, Nonvolatile Memory, Automotive, and Multi-Market and Other.
Shares of The Interpublic Group of Companies, Inc. (NYSE:IPG), inclined 0.85% to $21.26, during its last trading session.
Weber Shandwick, part of the Interpublic Group of Companies, declared the appointment of several key hires in the firm’s San Francisco office across its Creative, Digital and Corporate ranks. Weber Shandwick’s Northern California region continues to expand its integrated communications and content marketing expertise following the appointment of Luca Penati as general manager, San Francisco and Silicon Valley, and Mediaco lead for the Western region late last year.
Jonathan Carroll has been designated senior vice president and will lead Weber Shandwick’s Digital and Creative teams in San Francisco. Carroll has nearly 15 years of experience working with top brands to execute digital campaigns across a variety of consumer and B2B verticals. He will work with clients across practices on content creation, digital strategy, social media engagement and creating interactive solutions across a wide variety of platforms.
The Interpublic Group of Companies, Inc. provides advertising and marketing services. The company operates in two segments, Integrated Agency Networks and Constituency Administration Group. It offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines.
At the end of Monday’s trade, Shares of Immunomedics Inc. (NASDAQ:IMMU), gained 2.43% to $4.22.
Immunomedics, declared that it has received notice from the U.S. Food and Drug Administration (FDA) designating as a Fast Track development program sacituzumab govitecan, the Company’s lead antibody-drug conjugate (ADC), for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have failed two preceding lines of therapy (counting targeted therapies such as an ALK inhibitor, EGFR inhibitor, and PD-1 inhibitor, if applicable) to demonstrate a clinically important and statistically robust improvement in overall survival over accessible therapies.
In a mid-stage clinical study in patients with advanced metastatic solid cancers who had failed multiple preceding therapies for their disease, sacituzumab govitecan produced promising therapeutic results in patients with several different cancer types, counting breast, lung, esophageal, colorectal, and urinary bladder cancers, with limited and tolerable side effects.
Formerly, FDA also granted Fast Track status to sacituzumab govitecan for the therapy of patients with triple-negative breast or small-cell lung cancers. Sacituzumab govitecan has also been designated an orphan drug by FDA for the treatment of patients with small-cell lung or pancreatic cancers.
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs comprise epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer.
Finally, JDS Uniphase Corporation (NASDAQ:JDSU), ended its last trade with 0.63% gain, and closed at $12.83.
On May 13, JDS Uniphase Corporation, declared that it has signed a definitive agreement with Amada Holdings Co., Ltd. of Japan, a manufacturer of machine tools for metal fabrication, to purchase up to $40 million of preferred stock of a partner of Lumentum Holdings Inc., the publicly-traded company that will result from the planned spin-off of the CCOP business unit from JDSU. The spin-off is predictable to happen in the third calendar quarter of 2015 and the final amount of Amada’s investment will be determined based on initial trading of Lumentum Holdings Inc. common stock.
JDS Uniphase Corporation provides network and service enablement solutions and optical products worldwide. The company’s Network and Service Enablement segment offers network and service enablement solutions that enable the design, development, deployment, and maintenance of communication equipment and networks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
